Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
A 12-week with possible extension, phase II study to compare efficacy and safety of masitinib
at 3 and 6 mg/kg/day in combination with methotrexate, in treatment of patients with active
rheumatoid arthritis refractory to standard treatments.